Document Detail


The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure.
MedLine Citation:
PMID:  16724011     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite the availability of a variety of effective antihypertensive drugs, inadequate control of blood pressure is common in hypertensive patients. The aim of this study was investigate whether the alpha-adducin G460W polymorphism or angiotensinogen M235T polymorphism has an effect on the mean difference in blood pressure in subjects using antihypertensive drugs. Data from the Rotterdam Study, a population-based prospective cohort study in the Netherlands, was used. This study started in 1990 and included 7983 subjects of 55 years and older. Data from three examination rounds were used. Subjects were included when their blood pressure was elevated at 1 or more examinations and/or a diuretic, beta-blocker, calcium antagonist, or ACE inhibitor was used. A marginal generalized linear model was used to assess the drug-gene interaction. In total, 3025 hypertensives were included. No drug-gene interaction on blood pressure levels was found. The mean difference in systolic blood pressure (SBP) between subjects with the W-allele and GG genotype of the alpha-adducin gene was for diuretic users 1.25 mmHg (95% CI:-2.86 to 5.35), for beta-blockers 0.02 mmHg (95% CI:-3.39 to 3.42), for calcium antagonists -0.70 mmHg (95% CI:-5.61 to 4.21), and for ACE inhibitors -3.50 mmHg (95% CI:-9.02 to 2.02). The mean difference in SBP between subjects with the TT and MM genotype was for diuretic users -2.33 mmHg (95% CI:-8.32 to 3.66), for beta-blocker -0.06 mmHg (95% CI:-4.91 to 4.79), for calcium antagonist 0.59 mmHg (95% CI:-5.95 to 7.13), and for ACE inhibitor -2.33 mmHg (95% CI:-9.66 to 5.01). The G460W polymorphism and the M235T polymorphism did not modify the difference in blood pressure levels among subjects who used diuretics, beta-blockers, calcium antagonists, or ACE inhibitors.
Authors:
Hedi Schelleman; Olaf H Klungel; Jacqueline C M Witteman; Albert Hofman; Cornelia M van Duijn; Anthonius de Boer; Bruno H C H Stricker
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-05-17
Journal Detail:
Title:  European journal of human genetics : EJHG     Volume:  14     ISSN:  1018-4813     ISO Abbreviation:  Eur. J. Hum. Genet.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-22     Completed Date:  2006-08-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9302235     Medline TA:  Eur J Hum Genet     Country:  England    
Other Details:
Languages:  eng     Pagination:  860-6     Citation Subset:  IM    
Affiliation:
Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Aged
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Angiotensinogen / genetics*
Antihypertensive Agents / therapeutic use*
Calcium Channel Blockers / therapeutic use
Calmodulin-Binding Proteins / genetics*
Cohort Studies
Diuretics / therapeutic use
Female
Humans
Hypertension / drug therapy*,  genetics
Male
Middle Aged
Polymorphism, Genetic
Retrospective Studies
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Calmodulin-Binding Proteins; 0/Diuretics; 0/adducin; 11002-13-4/Angiotensinogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A locus for sacral/anorectal malformations maps to 6q25.3 in a 0.3 Mb interval region.
Next Document:  Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpoly...